Effects of ketanserin tartrate on serum lipids in patients with essential hypertension.

Abstract:

:Several antihypertensive agents such as thiazide diuretics and some beta-blockers have recently been shown to adversely affect lipid metabolism. Moreover, there is a growing suspicion that the adverse effect on plasma lipids might outweigh the favourable effect of lowering blood pressure. The effect of ketanserin tartrate (20 to 60 mg daily), a new antihypertensive drug, on blood lipids was evaluated in a 12-week non-comparative clinical trial in 34 patients with mild or moderate hypertension. Ketanserin reduced systolic and diastolic blood pressure by 12.2 and 9.8%, respectively, without altering heart rates. Total cholesterol and low density lipoprotein (LDL)-cholesterol levels in the fasting plasma were observed to decrease significantly by 6.3 and 8.8% respectively, whereas mean triglyceride and high density lipoprotein (HDL)-cholesterol remained almost unchanged. These changes were consistent irrespective of their initial values. Significant decrease in apolipoprotein B and E was also observed. Apolipoprotein A-I, A-II, C-II and C-III were not altered significantly. It is speculated that ketanserin affects mainly LDL-cholesterol. Based on these findings, ketanserin is considered to have a potentially beneficial effect on coronary risk profile and should be given full consideration when drug therapy is selected for patients with mild to moderate hypertension.

journal_name

Drugs

journal_title

Drugs

authors

Nakamura H,Hirata F,Yasugi T,Mizuno M,Saito E,Ishikawa T,Tada N,Nakaya N,Homma Y,Takeuchi I

doi

10.2165/00003495-198800361-00006

subject

Has Abstract

pub_date

1988-01-01 00:00:00

pages

25-34

eissn

0012-6667

issn

1179-1950

journal_volume

36 Suppl 1

pub_type

临床试验,杂志文章

相关文献

DRUGS文献大全
  • Efficacy and safety of postdischarge administration of enoxaparin in the prevention of deep venous thrombosis after total hip replacement. A prospective randomised double-blind placebo-controlled trial.

    abstract::Although venous thromboembolism has occasionally been reported after hospital discharge in patients who have undergone total hip replacement (THR), this risk has not been fully quantified and the usefulness of a prophylactic treatment has not been evaluated. We conducted a single-centre prospective randomised double-b...

    journal_title:Drugs

    pub_type: 临床试验,杂志文章,随机对照试验

    doi:10.2165/00003495-199600527-00009

    authors: Planes A,Vochelle N,Darmon JY,Fagola M,Bellaud M,Compan D,Saliba E,Weisslinger N,Huet Y

    更新日期:1996-01-01 00:00:00

  • Nateglinide.

    abstract::Nateglinide is a novel D-phenylalanine derivative that inhibits ATP-sensitive K+ channels in pancreatic beta-cells in the presence of glucose and thereby stimulates the prandial release of insulin. Nateglinide reduces fasting and mealtime blood glucose levels in animals, healthy volunteers, and patients with type 2 (n...

    journal_title:Drugs

    pub_type: 杂志文章,评审

    doi:10.2165/00003495-200060030-00007

    authors: Dunn CJ,Faulds D

    更新日期:2000-09-01 00:00:00

  • Systematic review and guide to selection of selective serotonin reuptake inhibitors.

    abstract::A meta-analysis of 20 short term comparative studies of 5 selective serotonin reuptake inhibitors (SSRIs; citalopram, fluoxetine, fluvoxamine, paroxetine and sertraline) has shown no difference in efficacy between individual compounds but a slower onset of action of fluoxetine. There were suggestions that fluoxetine c...

    journal_title:Drugs

    pub_type: 杂志文章,meta分析

    doi:10.2165/00003495-199957040-00005

    authors: Edwards JG,Anderson I

    更新日期:1999-04-01 00:00:00

  • Rupatadine: a review of its use in the management of allergic disorders.

    abstract::Rupatadine (Rupafin, Rinialer, Rupax, Alergoliber) is a selective oral histamine H(1)-receptor antagonist that has also been shown to have platelet-activating factor (PAF) antagonist activity in vitro. It is indicated for use in seasonal allergic rhinitis (SAR), perennial allergic rhinitis (PAR) and chronic idiopathic...

    journal_title:Drugs

    pub_type: 杂志文章,评审

    doi:10.2165/00003495-200767030-00008

    authors: Keam SJ,Plosker GL

    更新日期:2007-01-01 00:00:00

  • Damoctocog Alfa Pegol: A Review in Haemophilia A.

    abstract::Damoctocog alfa pegol (Jivi®) is approved in the USA, EU, Japan and Canada for the treatment and prophylaxis of previously treated patients aged ≥ 12 years with haemophilia A. Formulated with a 60 kDa polyethylene glycol (PEG) moiety, damoctocog alfa pegol is an intravenously (IV) administered recombinant factor VIII ...

    journal_title:Drugs

    pub_type: 杂志文章,评审

    doi:10.1007/s40265-019-01152-7

    authors: Paik J,Deeks ED

    更新日期:2019-07-01 00:00:00

  • Rho-Associated Kinase Inhibitors: Evolving Strategies in Glaucoma Treatment.

    abstract::Glaucoma, a group of progressive optic neuropathies with similar patterns of tissue loss, is primarily treated with medical therapy, followed by laser therapy and, later, incisional surgery. Aside from the introduction of prostaglandin analogs, topical carbonic anhydrase inhibitors, and topical alpha-agonists in the 1...

    journal_title:Drugs

    pub_type: 杂志文章,评审

    doi:10.1007/s40265-019-01130-z

    authors: Schehlein EM,Robin AL

    更新日期:2019-07-01 00:00:00

  • Aliskiren/hydrochlorothiazide combination: in mild to moderate hypertension.

    abstract::Aliskiren/hydrochlorothiazide is a single-pill combination of the first in the new class of non-peptide direct renin inhibitors (aliskiren) and a thiazide diuretic (hydrochlorothiazide [HCTZ]) that achieves blood pressure (BP) reductions greater than those seen with either component alone. In double-blind, 8-week clin...

    journal_title:Drugs

    pub_type: 杂志文章

    doi:10.2165/00003495-200969070-00004

    authors: Baldwin CM,Plosker GL

    更新日期:2009-01-01 00:00:00

  • Pancreatic islet cell transplantation: likely impact on current therapeutics for type 1 diabetes mellitus.

    abstract::Pancreatic islet transplantation as a cell-based treatment for diabetes mellitus has been pursued for over quarter of a century, ever since the first successful use of this approach to cure diabetes mellitus in rodents in the 1970s. However, even though autoislet intrahepatic transplantation in patients with chronic p...

    journal_title:Drugs

    pub_type: 杂志文章

    doi:10.2165/00003495-200161140-00001

    authors: Robertson RP

    更新日期:2001-01-01 00:00:00

  • Appropriate use of antitussives and protussives. A practical review.

    abstract::As a symptom of an underlying condition, cough is one of the most common reasons patients see physicians. To the majority, a cough means that 'something is wrong' and it causes exhaustion and/or self-consciousness. Patients find these reasons as well as effects on lifestyle, fear of cancer and/or AIDS or tuberculosis ...

    journal_title:Drugs

    pub_type: 杂志文章,评审

    doi:10.2165/00003495-199346010-00006

    authors: Irwin RS,Curley FJ,Bennett FM

    更新日期:1993-07-01 00:00:00

  • Effect of a single dose of cefotaxime or ceftriaxone on human faecal flora. A double-blind study.

    abstract::The effect of cefotaxime and ceftriaxone on faecal flora was investigated in women undergoing routine vaginal or abdominal hysterectomy. Three groups of 9 patients received, in a double-blind fashion and just before surgery, cefotaxime 2g intravenously, ceftriaxone 2g intravenously or no antibiotic (controls). Stools ...

    journal_title:Drugs

    pub_type: 临床试验,杂志文章

    doi:10.2165/00003495-198800352-00004

    authors: Michéa-Hamzehpour M,Auckenthaler R,Kunz J,Pechère JC

    更新日期:1988-01-01 00:00:00

  • Intravenous Minocycline: A Review in Acinetobacter Infections.

    abstract::Intravenous minocycline (Minocin®) is approved in the USA for use in patients with infections due to susceptible strains of Gram-positive and Gram-negative pathogens, including infections due to Acinetobacter spp. Minocycline is a synthetic tetracycline derivative that was originally introduced in the 1960s. A new int...

    journal_title:Drugs

    pub_type: 杂志文章,评审

    doi:10.1007/s40265-016-0636-6

    authors: Greig SL,Scott LJ

    更新日期:2016-10-01 00:00:00

  • Optimum management of the discharging ear.

    abstract::Discharge from the ear can be the result of many disease processes. The ear may discharge blood, pus, cerebrospinal fluid (CSF) or wax. Keratosis obturans, stenosis of the external meatus and benign tumours of the external meatus all lead to wax build-up, which may cause recurrent attacks of otitis externa. Malignant ...

    journal_title:Drugs

    pub_type: 杂志文章,评审

    doi:10.2165/00003495-199243020-00008

    authors: Ruddy J,Bickerton RC

    更新日期:1992-02-01 00:00:00

  • Treating ocular hypertension to reduce glaucoma risk: when to treat?

    abstract::When to treat the patient who presents with ocular hypertension has been a question that has 'stumped' the ophthalmic community for decades. Population-based studies and intervention trials have provided the basis for understanding why we consider treating such patients. Although the EGPS (European Glaucoma Prevention...

    journal_title:Drugs

    pub_type: 杂志文章,评审

    doi:10.2165/00003495-200666080-00001

    authors: Higginbotham EJ

    更新日期:2006-01-01 00:00:00

  • Drug treatment of hypertension.

    abstract::There are several first choices for the treatment of mild and moderate hypertension. The selection of a drug may be influenced by concomitant pathology, with positive indications for particular drugs, e.g. coexistent angina, indicating use of a beta-receptor blocking drug or calcium antagonist; fluid retention indicat...

    journal_title:Drugs

    pub_type: 杂志文章,评审

    doi:10.2165/00003495-198800356-00006

    authors: Prichard BN

    更新日期:1988-01-01 00:00:00

  • Drug treatment of scleroderma.

    abstract::Scleroderma or systemic sclerosis is a rare condition with many clinical manifestations including Raynaud's phenomenon. As with many other rarely encountered diseases, drug therapy for scleroderma is often empirical with little evidence in the form of randomised controlled trials to aid drug choice. Raynaud's phenomen...

    journal_title:Drugs

    pub_type: 杂志文章,评审

    doi:10.2165/00003495-200161030-00008

    authors: Leighton C

    更新日期:2001-01-01 00:00:00

  • Selection of vasodilator drugs for patients with severe chronic heart failure: an approach based on a new classification.

    abstract::Although vasodilator drugs are of proven worth in the management of patients with severe heart failure, a useful system of classification of vasodilator drugs has not yet been devised. The traditional system of classification based on the dominant arterial and/or venous sites of action as determined by limb plethysmog...

    journal_title:Drugs

    pub_type: 杂志文章,评审

    doi:10.2165/00003495-198224010-00003

    authors: Packer M

    更新日期:1982-07-01 00:00:00

  • Induction therapy in renal transplant recipients: how convincing is the current evidence?

    abstract::The goal of organ transplantation is to provide durable organ function while minimizing risks such as infection and cancer. Induction therapy in renal transplantation provides improved short- and long-term graft outcomes compared with placebo. Three agents are currently available and widely used in the US; rabbit anti...

    journal_title:Drugs

    pub_type: 杂志文章,评审

    doi:10.2165/11631300-000000000-00000

    authors: Wagner SJ,Brennan DC

    更新日期:2012-03-26 00:00:00

  • HMG-CoA reductase inhibitors in chronic heart failure: potential mechanisms of benefit and risk.

    abstract::HMG-CoA reductase inhibitors (statins) have been shown to reduce mortality and cardiovascular morbidity in patients with hyperlipidaemia and those with coronary artery disease. However, evidence for statin treatment in patients with chronic heart failure (CHF) remains a subject of debate. Patients with heart failure w...

    journal_title:Drugs

    pub_type: 杂志文章,评审

    doi:10.2165/00003495-200666020-00002

    authors: Laufs U,Custodis F,Böhm M

    更新日期:2006-01-01 00:00:00

  • Inhaled tobramycin (TOBI): a review of its use in the management of Pseudomonas aeruginosa infections in patients with cystic fibrosis.

    abstract::Specifically formulated for nebulisation using the PARI LC PLUS reusable nebuliser, tobramycin solution for inhalation (TSI) [TOBI] provides a high dose of tobramycin (an aminoglycoside antibacterial with good activity against Pseudomonas aeruginosa) to the lungs of patients with cystic fibrosis, while maintaining low...

    journal_title:Drugs

    pub_type: 杂志文章,评审

    doi:10.2165/00003495-200363220-00015

    authors: Cheer SM,Waugh J,Noble S

    更新日期:2003-01-01 00:00:00

  • An evaluation of pharmacological strategies for the prevention and treatment of acute renal failure.

    abstract::Acute renal failure (ARF) occurs frequently in hospitalised patients, and is associated with significant morbidity and mortality. The most common and generalised forms of acute renal failure are pre-renal conditions and intra-renal acute tubular necrosis (ATN). Pre-renal ARF in its pure state should be entirely revers...

    journal_title:Drugs

    pub_type: 杂志文章,评审

    doi:10.2165/00003495-200059010-00005

    authors: Dishart MK,Kellum JA

    更新日期:2000-01-01 00:00:00

  • Isradipine. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic use in cardiovascular disease.

    abstract::Isradipine, a dihydropyridine derivative, inhibits the inward calcium flux through 'slow' channels of cardiac and vascular tissue, thereby eliciting potent coronary, cerebral and peripheral vasodilatation. In comparison with other calcium channel blockers the drug offers the advantages of minimal cardiodepressant acti...

    journal_title:Drugs

    pub_type: 杂志文章,评审

    doi:10.2165/00003495-199040010-00004

    authors: Fitton A,Benfield P

    更新日期:1990-07-01 00:00:00

  • Telavancin.

    abstract::Telavancin is the first available lipoglycopeptide antibacterial agent. It is active against Gram-positive bacteria, including meticillin/oxacillin-resistant Staphylococcus aureus (MRSA) strains associated with complicated skin and skin structure infections (cSSSIs). In randomized, double-blind trials, intravenous tel...

    journal_title:Drugs

    pub_type: 杂志文章

    doi:10.2165/10481380-000000000-00000

    authors: Lyseng-Williamson KA,Blick SK

    更新日期:2009-01-01 00:00:00

  • Comparative efficacy, safety and pharmacokinetics of verapamil SR vs verapamil IR in hypertensive patients.

    abstract::The antihypertensive effects of the regular immediate release formulation of verapamil (verapamil IR) and the newer sustained release formulation of verapamil (verapamil SR) were compared in Hispanic patients with untreated essential hypertension. Verapamil IR was given in 3 divided doses (80 or 160mg 3 times daily) a...

    journal_title:Drugs

    pub_type: 临床试验,杂志文章,随机对照试验

    doi:10.2165/00003495-199200441-00002

    authors: Fuenmayor NT,Faggin BM,Cubeddu LX

    更新日期:1992-01-01 00:00:00

  • Tissue-type plasminogen activator. A review of its pharmacology and therapeutic use as a thrombolytic agent.

    abstract::Coronary arterial thrombolysis is becoming an established treatment of acute myocardial infarction. If given early enough, it recanalises occluded coronary arteries, salvages myocardial function and reduces mortality. A reduction of mortality in patients with acute myocardial infarction has now been demonstrated for s...

    journal_title:Drugs

    pub_type: 杂志文章,评审

    doi:10.2165/00003495-198938030-00003

    authors: Collen D,Lijnen HR,Todd PA,Goa KL

    更新日期:1989-09-01 00:00:00

  • Current and potential pharmacological treatment options for maintenance therapy in opioid-dependent individuals.

    abstract::Opioid dependence, manifesting as addiction to heroin and pharmaceutical opioids is increasing. Internationally, there are an estimated 15.6 million illicit opioid users. The global economic burden of opioid dependence is profound both in terms of HIV and hepatitis C virus transmission, direct healthcare costs, and in...

    journal_title:Drugs

    pub_type: 杂志文章,评审

    doi:10.2165/11597520-000000000-00000

    authors: Tetrault JM,Fiellin DA

    更新日期:2012-01-22 00:00:00

  • Combination antiretroviral therapy. Back to the future.

    abstract::HIV causes chronic infection and is associated with persistent viral replication and a high viral mutation rate. It is an illusion to think that monotherapy with any antiretroviral agent will have a major and lasting impact on this disease. Monotherapy with antitubercular agents led to dramatic improvements in treatme...

    journal_title:Drugs

    pub_type: 杂志文章,评审

    doi:10.2165/00003495-199500491-00008

    authors: Lange J

    更新日期:1995-01-01 00:00:00

  • Insulin glargine: an updated review of its use in the management of diabetes mellitus.

    abstract::Insulin glargine is a human insulin analogue prepared by recombinant DNA technology. Modification of the human insulin molecule at position A21 and at the C-terminus of the B-chain results in the formation of a stable compound that is soluble at pH 4.0, but forms amorphous microprecipitates in subcutaneous tissue from...

    journal_title:Drugs

    pub_type: 临床试验,杂志文章,多中心研究,随机对照试验,评审

    doi:10.2165/00003495-200363160-00007

    authors: Dunn CJ,Plosker GL,Keating GM,McKeage K,Scott LJ

    更新日期:2003-01-01 00:00:00

  • HDL-cholesterol as a risk factor in coronary heart disease. An update of the Helsinki Heart Study.

    abstract::The aim of the Helsinki Heart Study, a 5-year primary prevention placebo-controlled study involving 4081 dyslipidaemic men (aged 40 to 55 years), was to investigate if increasing high density lipoprotein (HDL)-cholesterol plasma levels and decreasing low density lipoprotein (LDL)-cholesterol levels would reduce the in...

    journal_title:Drugs

    pub_type: 临床试验,杂志文章,随机对照试验

    doi:10.2165/00003495-199000401-00004

    authors: Frick MH,Manninen V,Huttunen JK,Heinonen OP,Tenkanen L,Mänttäri M

    更新日期:1990-01-01 00:00:00

  • Macitentan: a review of its use in patients with pulmonary arterial hypertension.

    abstract::Macitentan (Opsumit(®)) is an orally active, dual endothelin receptor antagonist (ERA) with tissue targeting properties. Macitentan was approved recently in the EU (as monotherapy or combination therapy) for the long-term treatment of pulmonary arterial hypertension (PAH) in adults of WHO functional class II or III, a...

    journal_title:Drugs

    pub_type: 杂志文章,评审

    doi:10.1007/s40265-014-0266-9

    authors: Dhillon S

    更新日期:2014-09-01 00:00:00

  • Cholinesterase inhibitors for Alzheimer's disease.

    abstract::Alzheimer's disease (AD) is the most common age-related neurodegenerative disease and has become an urgent public health problem in most areas of the world. Substantial progress has been made in understanding the basic neurobiology of AD and, as a result, new drugs for its treatment have become available. Cholinestera...

    journal_title:Drugs

    pub_type: 杂志文章,评审

    doi:10.2165/00003495-200161010-00005

    authors: Grutzendler J,Morris JC

    更新日期:2001-01-01 00:00:00